The stock of Anavex Life Sciences Corporation (AVXL) has gone down by -0.22% for the week, with a -14.02% drop in the past month and a -51.24% drop in the past quarter. The volatility ratio for the week is 6.36%, and the volatility levels for the past 30 days are 5.69% for AVXL. The simple moving average for the past 20 days is -9.99% for AVXL’s stock, with a -34.36% simple moving average for the past 200 days.
Is It Worth Investing in Anavex Life Sciences Corporation (NASDAQ: AVXL) Right Now?
The stock has a 36-month beta value of 0.57. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AVXL is 79.52M, and at present, short sellers hold a 25.15% of that float. On April 03, 2024, the average trading volume of AVXL was 1.48M shares.
AVXL) stock’s latest price update
Anavex Life Sciences Corporation (NASDAQ: AVXL)’s stock price has dropped by -9.56 in relation to previous closing price of 5.02. Nevertheless, the company has seen a loss of -0.22% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-25 that NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.
Analysts’ Opinion of AVXL
Many brokerage firms have already submitted their reports for AVXL stocks, with Cantor Fitzgerald repeating the rating for AVXL by listing it as a “Neutral.” The predicted price for AVXL in the upcoming period, according to Cantor Fitzgerald is $11 based on the research report published on December 06, 2022 of the previous year 2022.
Berenberg, on the other hand, stated in their research note that they expect to see AVXL reach a price target of $40. The rating they have provided for AVXL stocks is “Buy” according to the report published on June 23rd, 2022.
BTIG Research gave a rating of “Buy” to AVXL, setting the target price at $35 in the report published on September 23rd of the previous year.
AVXL Trading at -17.22% from the 50-Day Moving Average
After a stumble in the market that brought AVXL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.56% of loss for the given period.
Volatility was left at 5.69%, however, over the last 30 days, the volatility rate increased by 6.36%, as shares sank -11.15% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.96% lower at present.
During the last 5 trading sessions, AVXL fell by -0.22%, which changed the moving average for the period of 200-days by -48.11% in comparison to the 20-day moving average, which settled at $5.02. In addition, Anavex Life Sciences Corporation saw -51.24% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AVXL starting from MISSLING CHRISTOPHER U, who sale 73,380 shares at the price of $5.11 back on Mar 28 ’24. After this action, MISSLING CHRISTOPHER U now owns 1,250,210 shares of Anavex Life Sciences Corporation, valued at $374,972 using the latest closing price.
MISSLING CHRISTOPHER U, the President and CEO of Anavex Life Sciences Corporation, sale 268,000 shares at $7.98 during a trade that took place back on Jun 28 ’23, which means that MISSLING CHRISTOPHER U is holding 1,018,210 shares at $2,139,310 based on the most recent closing price.
Stock Fundamentals for AVXL
The total capital return value is set at -0.36. Equity return is now at value -31.89, with -29.12 for asset returns.
Currently, EBITDA for the company is -47.5 million with net debt to EBITDA at 3.08. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.85.
Conclusion
To sum up, Anavex Life Sciences Corporation (AVXL) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
